Drug Database
Back to search

Netherlands· NL-5fbc50a832b1

Lytenava 25 mg/ml oplossing voor injectie

A bevacizumab product containing bevacizumab gamma, registered in Netherlands by Outlook Therapeutics NL B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC S01LA08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLytenava 25 mg/ml oplossing voor inje…ATCS01LA08REGISTER NO.NL-5fbc50a832b1PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bevacizumab gammaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bevacizumab is registered in 9 of 19 countries.

Countries holding a registration under ATC S01LA08 (bevacizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search bevacizumab products by name

Bevacizumab · ATC S01LA08

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BEVACIZUMAB GAMMA
Manufacturer
Outlook Therapeutics NL B.V.
Country
Netherlands (NL)
ATC code
S01LA08
ATC class
Bevacizumab
Defined daily dose
0.036 DE, IVT
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1798

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Bevacizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bevacizumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Oyavas
  • Iceland · Abevmy, Alymsys
  • Liechtenstein · Abevmy, Alymsys
  • Norway · Abevmy, Alymsys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ecf43482-e3b4-48cc-a5cb-c4028c55dd1d
GET /v1/drugs/ecf43482-e3b4-48cc-a5cb-c4028c55dd1d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Intravitreaal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lytenava-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Bevacizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130861",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "POLYSORBAAT 20 (E 432)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "TREHALOSE (Alpha, Alpha-)  2-WATER",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "BEVACIZUMAB GAMMA"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/05/27",
  "procedure_number": "EMEA/H/C/005723",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1798",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about bevacizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console